Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

n=6), neuropathy (n=3), development of an unrelated malignancy (glioblastoma) (n=1), reduced-intensity allogeneic transplantation (n=1). This is the first study to use internationally agreed response criteria for myelofibrosis (the EUMNET criteria) to evaluate response to thalidomide and prednisolone. Overall, 40% of patients achieved major or moderate responses by EUMNET criteria. All responses began within the first 12 weeks of treatment, suggesting that thalidomide could be stopped if there is no response by this time. Among responders, the median response duration was 16 weeks. Three patients lost their responses when prednisolone was withdrawn at 12 weeks. The 2 patients not treated with prednisolone appeared to have a less favourable response.